31
Participants
Start Date
September 30, 2019
Primary Completion Date
March 17, 2022
Study Completion Date
June 27, 2023
Placebo
Normal saline (0.9% NaCl) matching volume of cemdisiran doses were administered SC.
Cemdisiran
Cemdisiran was administered by SC injection.
Clinical Trial Site, Vancouver
Clinical Trial Site, Grenoble
Clinical Trial Site, La Tronche
Clinical Trial Site, Mulhouse
Clinical Trial Site, Kuala Lumpur
Clinical Trial Site, Kuantan
Clinical Trial Site, Serdang
Clinical Trial Site, Quezon City
Clinical Trial Site, Singapore
Clinical Trial Site, Córdoba
Clinical Trial Site, Girona
Clinical Trial Site, Huddinge
Clinical Trial Site, Uppsala
Clinical Trial Site, Taichung
Clinical Trial Site, Leicester
Clinical Trial Site, Brampton
Clinical Trial Site, Toronto
Lead Sponsor
Alnylam Pharmaceuticals
INDUSTRY